Annovis Bio, Inc. (ANVS)

Market Cap	32.15M
Revenue (ttm)	n/a
Net Income (ttm)	-24.59M
Shares Out	19.49M
EPS (ttm)	-2.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	402,941
Open	1.700
Previous Close	1.850
Day's Range	1.630 - 1.740
52-Week Range	1.530 - 20.000
Beta	1.65
Analysts	Strong Buy
Price Target	37.00 (+2,142.42%)
Earnings Date	Mar 21, 2025

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2020
• Employees: 16
• Stock Exchange: NYSE
• Ticker Symbol: ANVS
• Website: https://www.annovisbio.com

Analyst Forecast

According to 5 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price forecast is $37.0, which is an increase of 2,142.42% from the latest price.

Price Target

$37.0

(2,142.42% upside)

Analyst Consensus: Strong Buy